Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
Version v2-FR | Version v1-EN | |
---|---|---|
Language | French | English |
Date Updated | 2019-06-10 | 2019-06-10 |
Drug Identification Number | 01927604 | 01927604 |
Brand name | MYOCHRYSINE | MYOCHRYSINE |
Common or Proper name | Myochrysine 50mg | Myochrysine 50mg |
Company Name | SANOFI-AVENTIS CANADA INC | SANOFI-AVENTIS CANADA INC |
Ingredients | GOLD SODIUM THIOMALATE | GOLD SODIUM THIOMALATE |
Strength(s) | 50MG | 50MG |
Dosage form(s) | SOLUTION | SOLUTION |
Route of administration | INTRAMUSCULAR | INTRAMUSCULAR |
Packaging size | 5 ampoules | 5 ampoules |
ATC code | M01CB | M01CB |
ATC description | SPECIFIC ANTIRHEUMATIC AGENTS | SPECIFIC ANTIRHEUMATIC AGENTS |
Reason for discontinuation | Other (Please describe in comments) | Other (Please describe in comments) |
Anticipated discontinuation date | ||
Actual discontinuation date | 2019-06-04 | 2019-06-04 |
Remaining supply date | 2017-12-01 | 2017-12-01 |
Discontinuation status | Discontinued | Discontinued |
Discontinuation decision reversal | no | no |
Tier 3 Status | No | No |
Information on remaining supply | ||
Company comments | The continued global shortage of Myochrysine is due to manufacturing issues with the active ingredient. Consequently Sanofi has decided to discontinue all three strengths of Myochrysine globally. | The continued global shortage of Myochrysine is due to manufacturing issues with the active ingredient. Consequently Sanofi has decided to discontinue all three strengths of Myochrysine globally. |
Health Canada comments |